Celldex (TCE2) Stock Forecast & Price Target
TCE2 Analyst Ratings
Strong Buy
11Buy1Hold0Sell
Based on 12 analysts giving stock ratings to Celldex in the past 3 months
TCE2 Stock 12 Month Forecast
Average Price Target
EUR 59.23▲(124.35% Upside)Based on 12 Wall Street analysts offering 12 month price targets for Celldex in the last 3 months. The average price target is EUR 59.23 with a high forecast of EUR 89.52 and a low forecast of EUR 25.06. The average price target represents a 124.35% change from the last price of EUR 26.40.
Past 12 Months12 Month ForecastDec2025Sep2026
HighEUR 89.52
AverageEUR 59.23
LowEUR 25.06
Highest Price TargetHighestEUR 89.52Average Price TargetEUR 59.23Lowest Price TargetLowestEUR 25.06
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Judah Frommer | Morgan Stanley | EUR 51.02 | buy | 93.27%Upside | Assigned | 10/20/26 | ||
| Derek Archila | Wells Fargo | EUR 64.45 | buy | 144.13%Upside | Reiterated | 10/15/26 | ||
| Kristen Kluska | Cantor Fitzgerald | EUR 54.60→EUR 64.45 | buy | 144.13%Upside | Reiterated | 10/13/26 | ||
| Joseph Pantginis | H.C. Wainwright | EUR 57.29 | buy | 117.01%Upside | Reiterated | 10/05/26 | ||
| Richard Law CFA | Goldman Sachs | EUR 34.02→EUR 25.06 | hold | -5.06%Downside | Reiterated | 10/05/26 | ||
| Sam Slutsky | LifeSci Capital | EUR 50.13→EUR 57.29 | buy | 117.01%Upside | Reiterated | 10/03/26 | ||
| Edward Nash | Canaccord Genuity | EUR 53.71 | buy | 103.44%Upside | Reiterated | 09/23/26 | ||
| Thomas Smith | Leerink Partners | EUR 62.66→EUR 78.77 | buy | 198.38%Upside | Reiterated | 09/23/26 | ||
| Etzer Darout | Barclays | EUR 47.44 | buy | 79.71%Upside | Reiterated | 09/22/26 | ||
| Alex Thompson CFA | Stifel Nicolaus | EUR 51.92→EUR 60.87 | buy | 130.57%Upside | Assigned | 09/22/26 | ||
| Yatin Suneja | Guggenheim | EUR 89.52 | buy | 239.07%Upside | Reiterated | 09/22/26 | ||
 Unknown AnalystNot Ranked | Jefferies | EUR 60.87 | buy | 130.57%Upside | Reiterated | 08/07/26 | ||
| David Dai | UBS | EUR 40.28 | buy | 52.58%Upside | Reiterated | 06/16/26 | ||
| Andy Chen | Wolfe Research | EUR 45.65→EUR 39.39 | buy | 49.19%Upside | Reiterated | 06/14/26 | ||
| Yaron Werber | TD Cowen | ― | buy | ― | Reiterated | 05/07/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Judah Frommer | 10/20/26 | EUR 51.02 | buy | 93.27%Upside | Assigned | Morgan Stanley | ||
| Derek Archila | 10/15/26 | EUR 64.45 | buy | 144.13%Upside | Reiterated | Wells Fargo | ||
| Kristen Kluska | 10/13/26 | EUR 54.60→EUR 64.45 | buy | 144.13%Upside | Reiterated | Cantor Fitzgerald | ||
| Joseph Pantginis | 10/05/26 | EUR 57.29 | buy | 117.01%Upside | Reiterated | H.C. Wainwright | ||
| Richard Law CFA | 10/05/26 | EUR 34.02→EUR 25.06 | hold | -5.06%Downside | Reiterated | Goldman Sachs | ||
| Sam Slutsky | 10/03/26 | EUR 50.13→EUR 57.29 | buy | 117.01%Upside | Reiterated | LifeSci Capital | ||
| Edward Nash | 09/23/26 | EUR 53.71 | buy | 103.44%Upside | Reiterated | Canaccord Genuity | ||
| Thomas Smith | 09/23/26 | EUR 62.66→EUR 78.77 | buy | 198.38%Upside | Reiterated | Leerink Partners | ||
| Etzer Darout | 09/22/26 | EUR 47.44 | buy | 79.71%Upside | Reiterated | Barclays | ||
| Alex Thompson CFA | 09/22/26 | EUR 51.92→EUR 60.87 | buy | 130.57%Upside | Assigned | Stifel Nicolaus | ||
| Yatin Suneja | 09/22/26 | EUR 89.52 | buy | 239.07%Upside | Reiterated | Guggenheim | ||
| Unknown AnalystNot Ranked | 08/07/26 | EUR 60.87 | buy | 130.57%Upside | Reiterated | Jefferies | ||
| David Dai | 06/16/26 | EUR 40.28 | buy | 52.58%Upside | Reiterated | UBS | ||
| Andy Chen | 06/14/26 | EUR 45.65→EUR 39.39 | buy | 49.19%Upside | Reiterated | Wolfe Research | ||
| Yaron Werber | 05/07/26 | ― | buy | ― | Reiterated | TD Cowen |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Celldex
3 Months
Success Rate10/16 ratings generated profit
63%
Average Return
+2.82%
Copying Joseph Pantginis's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +2.82% per trade.
1 Year
Success Rate15/25 ratings generated profit
60%
Average Return
+63.32%
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +63.32% per trade.
2 Years
Success Rate9/15 ratings generated profit
60%
Average Return
+3.79%
Copying Derek Archila's trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +3.79% per trade.
TCE2 Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 6 | 14 | 14 | 20 | 17 |
| Buy | 9 | 11 | 14 | 11 | 8 |
| Hold | 1 | 2 | 2 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 16 | 27 | 30 | 35 | 29 |
In the current month, TCE2 has received 25 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. TCE2 average Analyst price target in the past 3 months is 59.23.
TCE2 Financial Forecast
HighEUR -0.84
ConsensusEUR -0.91
LowEUR -0.96
TCE2 Earnings Forecast
Next quarter’s earnings estimate for TCE2 is -EUR 0.91 with a range of -EUR 0.96 to -EUR 0.84. The previous quarter’s EPS was -EUR 0.84. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 2.68M
ConsensusEUR 646K
LowEUR 0.00
TCE2 Sales Forecast
Next quarter’s sales forecast for TCE2 is EUR 646.44K with a range of EUR 0 to EUR 2.68M. The previous quarter’s sales results were EUR 19.67K. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
TCE2 Stock Forecast FAQ
What is DE:TCE2’s average 12-month price target, according to analysts?
Based on analyst ratings, Celldex’s 12-month average price target is €59.23.
What is DE:TCE2’s upside potential, based on the analysts’ average price target?
Celldex has 124.35% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Celldex a Buy, Sell or Hold?
Celldex has a consensus rating of Strong Buy, which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
What is Celldex’s share price target?
The average share price target for Celldex is €59.23. This is based on 12 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €89.52, and the lowest forecast is €25.06. The average share price target represents a 124.35% increase from the current price of €26.4.
What do analysts say about Celldex?
Celldex’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Street analysts.
How can I buy shares of Celldex?
To buy shares of DE:TCE2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
